Provided by Tiger Trade Technology Pte. Ltd.

Capricor Therapeutics

9.47
+0.900010.50%
Post-market: 9.46-0.0101-0.11%19:59 EDT
Volume:20.57M
Turnover:208.71M
Market Cap:550.58M
PE:-3.84
High:10.72
Open:10.03
Low:9.40
Close:8.57
52wk High:40.37
52wk Low:2.96
Shares:58.14M
Float Shares:42.60M
Volume Ratio:8.40
T/O Rate:48.28%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4659
EPS(LYR):-2.2601
ROE:-73.70%
ROA:-33.63%
PB:2.24
PE(LYR):-4.19

Loading ...

Capricor Publishes Advisory Committee Presentation on Deramiocel Clinical Data in Duchenne Muscular Dystrophy

Reuters
·
Jul 27

Capricor Disputes FDA Post-hoc Analyses of Deramiocel Data Ahead of July 29 Advisory Panel

Reuters
·
Jul 27

Capricor Therapeutics Shares Slide on Negative FDA Comments

Dow Jones
·
Jul 27

Capricor Therapeutics plunges after FDA posts deramiocel briefing notes

TIPRANKS
·
Jul 27

Oppenheimer would own Capricor Therapeutics into committee meeting

TIPRANKS
·
Jul 27

B. Riley Securities Reaffirms Their Buy Rating on Capricor Therapeutics (CAPR)

TIPRANKS
·
Jul 27

Capricor Therapeutics Shares Fall 68% After US FDA Flags Concerns over Its Duchenne Therapy

THOMSON REUTERS
·
Jul 27

FDA Staff Flags Concerns for Capricor's Duchenne Heart Disease Therapy

Reuters
·
Jul 27

Capricor Therapeutics Shares Fall 60% Premarket After FDA Staff Review Says Data for Co's Duchenne Cell Therapy Does not Provide Substantial Evidence of Effectiveness

THOMSON REUTERS
·
Jul 27

Capricor Therapeutics (CAPR) Secures New Headquarters Tied To FDA Decision On Deramiocel

Simply Wall St.
·
Jul 27

Longeveron Elects Deborah Ascheim to Board of Directors

Reuters
·
Jul 23

Capricor Therapeutics Signs Strategic Headquarters Lease Agreement

TIPRANKS
·
Jul 15

Capricor Therapeutics (CAPR) Stock Looks Overvalued As Its 442% Run Draws Focus

Simply Wall St.
·
Jul 05

Capricor CFO Anthony Bergmann Disposes of USD 732,158 in Common Shares

Reuters
·
Jun 30

Capricor Therapeutics Gets FDA Advisory Panel Meeting for Duchenne Therapy

MT Newswires Live
·
Jun 29

Capricor Therapeutics (CAPR) Is Down 6.8% After Positive Five-Year HOPE-2 DMD Data And FDA Update

Simply Wall St.
·
Jun 28

What's Going On With Capricor Therapeutics Stock On Friday?

Benzinga
·
Jun 27

Capricor Tumbles as FDA Panel Meet for Duchenne Cell Therapy Adds Risk Worries

Reuters
·
Jun 26

Capricor Therapeutics to Face FDA Advisory Panel Review of Deramiocel BLA in Duchenne Muscular Dystrophy

Reuters
·
Jun 26

Capricor announces FDA advisory committee meeting to review Deramiocel BLA

TIPRANKS
·
Jun 26